Advertisement

Komorbidität unter geriatrischen Aspekten

  • Ulrich Wedding
  • Thomas Schäffer
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Die Zahl alter Menschen und damit die Zahl alter Patienten mit Krebserkrankungen wird weiter zunehmen. Das mittlere Erkrankungsalter beträgt derzeit ca. 70 Jahre. Mit zunehmendem Alter nimmt aber nicht nur die Zahl der Krebserkrankungen zu, auch die Inzidenz und die Prävalenz nicht-maligner Erkrankungen steigen. Ein wesentlicher Aspekt, der alte von jungen Patienten mit Krebserkrankungen unterscheiden kann, ist daher das Vorliegen von Komorbiditäten bzw. das Bestehen einer Multimorbidität. Diese führt häufig zur Polypharmazie. Der nachfolgende Beitrag geht auf den Stellenwert von Komorbiditäten/Multimorbidität im Rahmen der Betreuung alter Patienten mit Krebserkrankungen ein. Er definiert Ko- bzw. Multimorbidität, beschreibt mögliche gemeinsame Ursachen von Ko- bzw. Multimorbidität und Krebserkrankungen, berichtet Daten zur Prävalenz, stellt Methoden der strukturierten Erfassung dar und bewertet die prognostische Relevanz und den Stellenwert im Rahmen von Therapieentscheidungen.

Literatur

  1. Albertsen PC et al (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156(1):127–132CrossRefPubMedGoogle Scholar
  2. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294(6):716–724CrossRefPubMedGoogle Scholar
  3. Caillet P et al (2014) Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment. Clin Interv Aging 9:1645–1660PubMedPubMedCentralGoogle Scholar
  4. Castro MA, Dedivitis RA, Ribeiro KC (2007) Comorbidity measurement in patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 69(3):146–152CrossRefPubMedGoogle Scholar
  5. Charlson ME et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMedGoogle Scholar
  6. Charlson M et al (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251CrossRefPubMedGoogle Scholar
  7. Coebergh JW et al (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52(12):1131–1136CrossRefPubMedGoogle Scholar
  8. Cristofanilli M et al (2005) Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103(6):1122–1128CrossRefPubMedGoogle Scholar
  9. Edwards BK et al (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120(9):1290–1314CrossRefPubMedGoogle Scholar
  10. Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36(4):453–471CrossRefPubMedGoogle Scholar
  11. Extermann M et al (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16(4):1582–1587CrossRefPubMedGoogle Scholar
  12. Fleming ST et al (1999) A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 37(6):601–614CrossRefPubMedGoogle Scholar
  13. Giles FJ et al (2007) The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624–627CrossRefPubMedGoogle Scholar
  14. Given B et al (2001) Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res 50(4):222–232CrossRefPubMedGoogle Scholar
  15. Goede V et al (2016) Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group. Leuk Lymphoma 57(4):789–796CrossRefPubMedGoogle Scholar
  16. Greenfield S et al (1987) Patterns of care related to age of breast cancer patients. JAMA 257(20):2766–2770CrossRefPubMedGoogle Scholar
  17. Greenfield S et al (1995) Development and testing of a new measure of case mix for use in office practice. Med Care 33(4 Suppl):AS47–AS55PubMedGoogle Scholar
  18. Hershman DL et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol 34(25):3014–3022CrossRefPubMedPubMedCentralGoogle Scholar
  19. Hurria A et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465CrossRefPubMedPubMedCentralGoogle Scholar
  20. Janssen-Heijnen ML et al (2005) Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res 124:89–107CrossRefPubMedGoogle Scholar
  21. Jorgensen TL et al (2012) Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer 106(7):1353–1360CrossRefPubMedPubMedCentralGoogle Scholar
  22. Kaplan MH, Feinstein AR (1974) The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27(7–8):387–404CrossRefPubMedGoogle Scholar
  23. Linn E S et al (1968) Cumulative illness rating scale. journal of American Geriarrics Society 16:622–626.Google Scholar
  24. Mandelblatt JS et al (2001) Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res 36(6 Pt 1):1085–1107PubMedPubMedCentralGoogle Scholar
  25. Newschaffer CJ et al (1998) Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci 53(5):M372–M378CrossRefPubMedGoogle Scholar
  26. Salvi F et al (2008) A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 56(10):1926–1931CrossRefPubMedGoogle Scholar
  27. Sarfati D (2012) Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol 65(9):924–933CrossRefPubMedGoogle Scholar
  28. Sarfati D et al (2016) Identifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survival. Asia Pac J Clin Oncol 12(1):e47–e56CrossRefPubMedGoogle Scholar
  29. Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120(2):104–110CrossRefPubMedGoogle Scholar
  30. Sogaard M et al (2013) The impact of comorbidity on cancer survival: a review. Clin Epidemiol 5(Suppl 1):3–29CrossRefPubMedPubMedCentralGoogle Scholar
  31. Sorror ML et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919CrossRefPubMedPubMedCentralGoogle Scholar
  32. St Germain D et al (2014) Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. J Oncol Pract 10(2):e73–e80CrossRefPubMedPubMedCentralGoogle Scholar
  33. Stier DM et al (1999) Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology 54(3):424–429CrossRefPubMedGoogle Scholar
  34. Valderas JM et al (2009) Defining comorbidity: implications for understanding health and health services. Ann Fam Med 7(4):357–363CrossRefPubMedPubMedCentralGoogle Scholar
  35. Wedding U, Höffken K (2002) Komorbiditäten. In: Höffken K, Kolb G, Wedding U (Hrsg) Geriatrische Onkologie. Springer, HeidelbergGoogle Scholar
  36. Wedding U, Pientka L, Hoffken K (2007a) Quality-of-life in elderly patients with cancer: a short review. Eur J Cancer 43(15):2203–2210CrossRefPubMedGoogle Scholar
  37. Wedding U et al (2007b) Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol 61(3):269–276CrossRefPubMedGoogle Scholar
  38. Welch HG et al (1996) Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 124(6):577–584CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung für PalliativmedizinKlinik für Innere Medizin II, Universitätsklinikum JenaJenaDeutschland
  2. 2.Klinik Eilenburg, Innere MedizinKreiskrankenhaus Delitzsch GmbHEilenburgDeutschland

Section editors and affiliations

  • Matthias Ebert
    • 1
  1. 1.II. Medizinische KlinikUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations